ஜர்னல் ஆஃப் ஹெல்த் & மெடிக்கல் இன்பர்மேட்டிக்ஸ்

Abstract Background:

The objective of this study is to investigate hospital performance using an emerging analytics approach. Given that hospital care accounts for a large segment of healthcare spending, it is essential that hospital performance be measured over time to determine whether and where there is room for improvement in some of its critical success factors, and if there are savings to be found. Methods: Employing indicators such as hospital cost, in-hospital death rate, length of hospital stay, and the number of discharges from the hospital, we look at the trends for these indicators over a 10-year period. Data was extracted from the National Statistics Database of the Healthcare Cost and Utilization Project (HCUP.net), and Cognos and Tableau were used as visualization and analysis tools. Results: Our central finding is that over the 10-year analysis period, U.S. hospitals improved in several areas, including reduction in length of stay in hospitals, reduction in number of in-hospital deaths, and increase in number of discharges from hospitals. Despite these improvements, however, the cost of healthcare rose significantly. Conclusions: We show how healthcare administrators can learn from past performance in determining where to focus attention and improve outcomes. We also present a global perspective of healthcare and propose how critical it is for the U.S. to focus on major reduction in healthcare costs, beginning with hospital charges.

Abstract

The present study was focused on development of the potential compound containing 2-substituent-1Hbenzimidazole- 4-carboxamide derivatives against enteroviruses using QSAR studies. We discussed the twodimensional QSAR studies of 2-substituent-1H-benzimidazole-4-carboxamide analogues to elucidate the structural properties required for enteroviruses activity. The 2D-QSAR studies were performed using multiple linear regressions, giving square of correlation coefficient (r2)=0.7458, cross validated squared correlation coefficient (q2)=0.7128 and predictable ability (pred_r2)=0.7092. The present study reveals that presence of less bulky group at R1 position of benzimidazole scaffold increase the enteroviruses activity. We hope that the current study provides better insight into the designing and development of more potent benzimidazole-4-carboxamide inhibitors as enteroviruses drug in the future.